Motif Bio (LSE: MTFB) is a late clinical stage antibiotic development company. It announced today that it has appointed Fulford Group Ltd, a specialist adviser to help in establishing commercial
Graham Lumsden, CEO of Motif Bio, stated: “The future commercialisation of iclaprim is a key driver of value for the business, particularly its potential as an antibiotic treatment for serious
Motif Bio’s Dr Graham Lumsden discusses the first patient dosed in the Iclaprim Phase III trials in this exclusive interview with DirectorsTalk
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, yesterday announced the dosing of the first patient in two Phase 3 clinical trials of its lead
Motif Bio Plc (LON:MTFB) CEO Dr Graham Lumsden talks to DirectorsTalk about the dosing of the first patient in the iclaprim Phase 3 trials to treat skin infections. Graham explains
Northland Capital partners view: Motif is now an important step closer to bringing its flagship antibiotic iclaprim to market. Having commenced patient dosing in its pivotal Phase 3 trials, the
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk the dosing of the first patient in two Phase 3 clinical trials
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Motif Bio Plc 2 Reason
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today told DirectorsTalk that Dr. David Huang, Chief Medical Officer of Motif Bio, will participate in
Yesterday, Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
